To review the evidence on the effects of postnatal corticosteroids in preterm infants on long-term mortality and motor dysfunction, including cerebral palsy.
dose of dexamethasone (mg/kg) expected in the treated group; demographic details; rates of antenatal corticosteroid and postnatal surfactant therapy; and the ultimate use of postnatal steroids in infants initially allocated to placebo/control groups (contamination). Studies of other corticosteroids had the dose converted to the equivalent dose of dexamethasone. Results were expressed as event rate differences (ERD) and 95% confidence intervals (CI).
Methods of synthesis
How were the studies combined? Pooled event rate differences (ERD) and 95% confidence intervals (CI) were calculated.
How were differences between studies investigated? Sensitivity analyses for mortality were planned a priori and included trials where the following subgroups could be identified: time of starting therapy (< 5 days, 7 to 14 days, and > 14 days); dose of corticosteroid therapy above the median equivalent of dexamethasone (2.9 mg/kg); high (> 50%) rates of antenatal corticosteroid therapy: and surfactant therapy; and low contamination rate (<= 33%). Similarly, sensitivity analyses for motor dysfunction were also planned around postnatal age and the diagnosis of cerebral palsy.
Results of the review
Twenty-seven RCTs were included (3260 infants).
1. Overall mortality rate.
The latest age of reported mortality varied from 28 days to 3 years of age.
There was a non-significant difference between treatment groups favouring corticosteroids. ERD = -0.1% (95% CI: -2.9%, 2.8%). In no individual study was the reported mortality significantly different between groups. ERD ranged from -26.5% to + 16.7%.
After excluding two RCTs (early dexamethasone compared with selective dexamethasone at a later stage and dexamethasone started at 14 days compared with selective treatment at 28 days): difference between treatment groups was not significant. ERD = -0.7% (95% CI: -4.0%, 2.6%).
Mortality sensitivity analyses.
Postnatal age: mortality rate was non-significantly lower only in the subgroup with treatment starting between 7 and 14 days. Age < 7 days: ERD = 1.3% (95% CI: -2.3%, 4.9%). Age 7 to 14 days: ERD = -5.0 (95% CI: -11.0, 1.1). Age > 14 days: ERD = 0.3% (95% CI: -6.4%, 7.1%).
Rate of antenatal corticosteroids > 50%: there was a non-significant difference favouring the control group. ERD = 4.9% (95% CI: -1.5%, 11.4%).
There were no major differences in subgroup analyses restricted to higher dose of corticosteroids, where surfactant was given, or where contamination rate was low. Results were presented.
